MX2024010216A - Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico. - Google Patents

Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico.

Info

Publication number
MX2024010216A
MX2024010216A MX2024010216A MX2024010216A MX2024010216A MX 2024010216 A MX2024010216 A MX 2024010216A MX 2024010216 A MX2024010216 A MX 2024010216A MX 2024010216 A MX2024010216 A MX 2024010216A MX 2024010216 A MX2024010216 A MX 2024010216A
Authority
MX
Mexico
Prior art keywords
thienopyrrolotriazine
compounds
preparation
therapeutic use
formula
Prior art date
Application number
MX2024010216A
Other languages
English (en)
Spanish (es)
Inventor
Olivier Venier
Olivier Arnoud
Franck Caussanel
Rommel Dadji-Faihun
Gwladys Langot
Frank Marguet
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2024010216A publication Critical patent/MX2024010216A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024010216A 2022-02-21 2023-02-20 Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico. MX2024010216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22315036 2022-02-21
PCT/EP2023/054138 WO2023156643A1 (en) 2022-02-21 2023-02-20 Thienopyrrolotriazine compounds, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
MX2024010216A true MX2024010216A (es) 2024-09-02

Family

ID=81326677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010216A MX2024010216A (es) 2022-02-21 2023-02-20 Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico.

Country Status (11)

Country Link
US (1) US20250129091A1 (https=)
EP (1) EP4482841A1 (https=)
JP (1) JP2025506729A (https=)
KR (1) KR20240151767A (https=)
CN (1) CN118843632A (https=)
AU (1) AU2023222186A1 (https=)
CA (1) CA3244475A1 (https=)
CO (1) CO2024010803A2 (https=)
IL (1) IL314781A (https=)
MX (1) MX2024010216A (https=)
WO (1) WO2023156643A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116375728B (zh) * 2021-12-31 2025-06-10 成都赜灵生物医药科技有限公司 噻吩吡咯并三嗪酮类化合物及其用途
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210038877A (ko) * 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
JP2023523418A (ja) * 2020-04-23 2023-06-05 ヤンセン ファーマシューティカ エヌ.ベー. Nlrp3の阻害剤としての三環式化合物

Also Published As

Publication number Publication date
IL314781A (en) 2024-10-01
KR20240151767A (ko) 2024-10-18
US20250129091A1 (en) 2025-04-24
JP2025506729A (ja) 2025-03-13
CO2024010803A2 (es) 2024-08-20
CN118843632A (zh) 2024-10-25
EP4482841A1 (en) 2025-01-01
CA3244475A1 (en) 2023-08-24
WO2023156643A1 (en) 2023-08-24
AU2023222186A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
UY38793A (es) Compuestos químicos
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
CO2021004789A2 (es) Piridazinonas y sus métodos de uso
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
MX2020007014A (es) Compuestos de benzamida.
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
CO2024010803A2 (es) Compuestos de tienopirrolotriazina, su preparación y su uso terapéutico
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
MX387590B (es) Compuestos policíclicos como inhibidores de tirosina quinasa de bruton.
MX2022002053A (es) Conjugados de il-15 y sus usos.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
BR112022003982A2 (pt) Compostos heterocíclicos
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
BR112022003357A2 (pt) Compostos heterocíclicos
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
CL2021003228A1 (es) Compuestos tricíclicos y su uso
PY2021592A (es) Arilamidinas fungicidas
WO2020242719A3 (en) Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof
EA202191477A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина